- Home
- IMNM vs WT Comparison
IMNM vs WT Comparison
Compare IMNM & WT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMNM | WT |
|---|---|---|
| Founded | 2006 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | IMNM | WT |
|---|---|---|
| Price | $23.15 | $19.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 3 |
| Target Price | ★ $32.80 | $17.67 |
| AVG Volume (30 Days) | 754.2K | ★ 3.0M |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 0.74% |
| EPS Growth | 51.40 | ★ 127.27 |
| EPS | N/A | ★ N/A |
| Revenue | $6,941,000.00 | ★ $493,753,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | $1,127.34 | $8.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.43 |
| 52 Week Low | $7.74 | $9.24 |
| 52 Week High | $27.65 | $19.29 |
Technical Indicators
Market Signals| Indicator | IMNM | WT |
|---|---|---|
| Relative Strength Index (RSI) | 51.67 | 67.24 |
| Support Level | $19.23 | $15.69 |
| Resistance Level | $25.10 | N/A |
| Average True Range (ATR) | 1.10 | 0.73 |
| MACD | -0.15 | 0.22 |
| Stochastic Oscillator | 40.14 | 93.23 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
About WT WisdomTree Inc.
WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.